The aim of this review is to examine the mechanistic insights and impact of LTLDA use in relation to cancer prevention and the possible anticancer potential of aspirin and the ACMs, including iron-chelating capacity and antioxidant potential, with emphasis on the targeting and inhibition of specific iron metabolic pathways, iron proteins, and other iron processes involved in colorectal and other cancers. Here, PROS1 is linked to cancer.